政策力挺+内需崛起，国产创新药正从“吞金兽”变成“现金牛”！港股通创新药ETF（520880）溢价资金狂涌

Core Viewpoint - The innovation drug sector in the A-share and Hong Kong markets is experiencing significant fluctuations, with notable movements in ETFs focused on innovative drug development, indicating strong capital inflows and market interest [1][3]. Group 1: ETF Performance - The A-share innovation drug ETF (562050) fell by 0.61%, ending a two-day rise, while the Hong Kong innovation drug ETF (520880) briefly rose over 1% before closing down 0.15% [1]. - The Hong Kong innovation drug ETF (520880) has seen premium trading, with over 5.1 billion yuan invested last week, reflecting strong demand [1][3]. Group 2: Component Stock Performance - Significant divergence in performance among major component stocks of the Hong Kong innovation drug ETF, with notable gains from companies like Shijiazhuang Pharmaceutical Group and Hansoh Pharmaceutical, while companies like Innovent Biologics faced declines [3]. - New component stocks have shown remarkable performance, with Yaojie Ankang-B surging by 115.58% and MIRXES-B and Ying'en Biotechnology-B rising by 25.91% and 13.18% respectively [3]. Group 3: Index Adjustments - The Hong Kong innovation drug ETF (520880) underwent a "purification" adjustment on September 8, removing CXO companies and focusing solely on 14 innovative drug development firms, enhancing its representation of the sector [4]. - The adjusted index aims to provide a more accurate reflection of the performance of China's innovative drug companies, with a focus on those solely engaged in drug development [4]. Group 4: Policy and Market Trends - Recent favorable policies, including a 30-day review channel for innovative drug clinical trial applications, are expected to accelerate drug development and enhance the quality of China's pharmaceutical industry [4][5]. - The domestic demand for innovative drugs is rising, transitioning from a "cash-burning" phase to becoming a "cash cow," indicating a shift towards sustainable revenue generation [5]. - Analysts suggest that the innovation drug sector remains a core focus within the pharmaceutical industry, with ongoing policy support and increasing global competitiveness [5].